- Home
- OPRA vs VCEL Comparison
OPRA vs VCEL Comparison
Compare OPRA & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRA | VCEL |
|---|---|---|
| Founded | 1996 | 1989 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OPRA | VCEL |
|---|---|---|
| Price | $18.52 | $40.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $21.50 | ★ $57.75 |
| AVG Volume (30 Days) | 315.8K | ★ 543.4K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $21.29 | $19.40 |
| Revenue Next Year | $15.34 | $18.24 |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $11.71 | $28.95 |
| 52 Week High | $21.06 | $43.57 |
Technical Indicators
Market Signals| Indicator | OPRA | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 69.45 |
| Support Level | $16.96 | $32.47 |
| Resistance Level | $19.31 | $42.04 |
| Average True Range (ATR) | 0.68 | 1.62 |
| MACD | 0.01 | 0.43 |
| Stochastic Oscillator | 53.60 | 94.18 |
Price Performance
Historical ComparisonAbout OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.